藥明康德(603259.SH):藥明一期擬認購珠海通和毓承三期投資合夥企業1.1億元份額
格隆匯1月27日丨藥明康德(603259.SH)公佈,北京時間2021年1月27日,公司全資子企業無錫藥明康德一期投資企業(有限合夥)(以下簡稱“藥明一期”)與珠海通和毓承投資管理合夥企業(有限合夥)(以下簡稱“普通合夥人”)、其他有限合夥人簽署合夥協議,約定由藥明一期認繳珠海通和毓承三期投資合夥企業(有限合夥)的1.10億元人民幣份額,約佔已募集投資基金份額的9.982%。藥明一期於本公吿日尚未支付投資款,後續將以自有資金根據合夥協議的要求履行投資款的支付義務。
投資基金將專注於生命科學和健康醫療行業的創新型投資機會,關注的技術和平台集中在國家大力扶持的新興戰略產業中和生命科學密切相關的領域。公司認為,投資基金的管理團隊在生命科學和醫療健康領域擁有豐富的投資經驗和廣泛的行業資源,能夠發掘該領域高質量的創新成果,並通過投資幫助此類早期企業獲得資金以加速其創新成果轉化。
公司以較低比例向投資基金進行投資並作為其有限合夥人,一方面有望使公司在投資風險可控的前提下,獲得風險投資相關的財務收益;另一方面,投資基金所針對的早期醫療健康領域的相關企業是本公司重要的潛在客户羣體,有助於公司進一步推進長尾戰略,豐富公司的客户羣,擴展公司的主營業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.